#30 - 🔬 Hybrid cells cure T1D in mice

Hey readers! 👋 This week's news is packed with research that's quietly reshaping how we think about T1D treatment, from immune system "resets" in mice to real-world data on how your AID system handles that late-night pizza. Let's dig in!

Stanford's hybrid cell therapy reverses T1D in mice - Researchers demonstrated that transplanting both blood-forming stem cells and pancreatic islet cells from a donor creates a "hybrid" immune system that stops the autoimmune attack on beta cells. All 19 pre-diabetic mice and 9 mice with established diabetes were cured without immunosuppressive drugs or graft-versus-host disease. The protocol uses clinically approved conditioning agents, making human trials a realistic next step. – ScienceDaily

CRISPR-edited cells produce insulin without immunosuppression - In a first-of-its-kind experiment, researchers implanted CRISPR-edited pancreatic cells into a man with T1D. The modified cells produced insulin for months without requiring immunosuppressive drugs, thanks to engineered "immune camouflage" that prevents the body from attacking them. – Ohio Society of Association Professionals

The Lancet reviews T1D's "transformative era" - A comprehensive review outlines three major advances: teplizumab (the first FDA-approved therapy to delay T1D onset), stem-cell-derived beta cells achieving insulin independence in early trials, and next-generation AID systems with ultrarapid and once-weekly insulins. The authors note that scalability, cost, and equitable access remain significant challenges. – The Lancet

Long-term Treg therapy shows lasting safety and efficacy - A follow-up study examined children who received autologous T regulatory cell therapy 7.5 to 12 years ago. Those who received combined Treg and anti-CD20 treatment showed significantly better C-peptide secretion, longer insulin independence, and extended remission periods. Importantly, no serious adverse events, tumors, or deaths were reported across more than 700 clinical measures. – Diabetes, Obesity and Metabolism

Anti-CD3 hydrogel protects transplanted beta cells - A new microporous hydrogel functionalized with anti-CD3 antibodies creates a protective niche for stem cell-derived beta cells, blocking T-cell migration and supporting rapid vascularization with minimal foreign-body response. – NIH

Omnipod 5 now works with Dexcom G7 15-Day sensor - Insulet announced immediate compatibility between Omnipod 5 and Dexcom's extended-wear G7 sensor for adults 18 and older. The G7 15-day offers up to 15.5 days of wear, 8% MARD accuracy, waterproofing, and Apple Watch connectivity. Insulet plans to add Abbott FreeStyle Libre 3 Plus compatibility by early next year. – Drug Delivery Business

MiniMed 780G meal management review - Real-world data from over 61,000 users confirms that the 780G maintains comparable time-in-range whether you bolus before eating or at meal start, though delays beyond 30 minutes lead to higher glucose spikes. The system can compensate for missed boluses up to 30g of carbs and handles high-fat, high-protein meals effectively. Optimal settings: 100 mg/dL glucose target, 2-hour active insulin time, and 2-3 carbohydrate ratios daily. – Diabetes, Obesity and Metabolism

CGM catches 25% more adverse events than fingersticks in hospitals - A multicenter study found that continuous glucose monitoring detected hyperglycemia 70 minutes earlier and hypoglycemia 38 minutes earlier than standard point-of-care testing in hospitalized T1D patients. A quarter of CGM-detected events were completely missed by fingerstick testing. – Diabetes Care

Abbott issues correction for Libre 3 sensors - Abbott has issued a correction affecting approximately 3 million Freestyle Libre 3 and 3 Plus sensors after discovering some units could produce inaccurate low glucose readings. The company has received reports of 736 severe adverse events and seven deaths worldwide associated with the issue. Check your sensors and contact Abbott if you have concerns. – The Savvy Diabetic

New blood test detects proinsulin variants for earlier diagnosis - University at Buffalo researchers developed an ultra-sensitive mass spectrometry platform that can detect and quantify low-abundance proinsulin proteoforms, providing detailed insight into beta-cell dysfunction across T1D stages. The technique could enable earlier diagnosis and better disease staging. – University at Buffalo

Multiplex assay screens for celiac and T1D simultaneously - A new flow cytometry-based test detects autoantibodies for both celiac disease and type 1 diabetes in a single run, reducing costs up to tenfold compared to traditional methods. – PubMed

T1DX-QI Learning Session highlights equity and AID adoption - More than 60 diabetes clinics gathered in Atlanta to share data on improving care. Key findings: standardized AID initiation protocols cut wait times by 40%, and targeted advocacy combined with workflow redesign significantly narrowed disparities in CGM and AID uptake among children and underserved populations. – T1D Exchange

Made with ❤️ by Data Drift Press

Have questions, comments, or feedback? Just hit reply - we'd love to hear from you!